(Circulation. 2002;106:2417.)
© 2002 American Heart Association, Inc.
Editorial |
From the Cardiovascular Division, Department of Medicine, University of Minnesota, Minneapolis.
Correspondence to Jay N. Cohn, MD, Cardiovascular Division, Mayo Mail Code 508, University of Minnesota, 420 Delaware St SE, Minneapolis, MN 55455. E-mail cohnx001@umn.edu
Key Words: Editorials nervous system, sympathetic heart failure
An extract of the first 250 words of the full text is provided, because this article has no abstract. |
For those who have comfortably accepted the mechanistic link between sympathetic nervous system activation and poor outcome in heart failure, the study by Brede et al1 in this issue of Circulation is a welcome confirmation. The authors appear to have demonstrated in a murine model that absence of sympathoinhibitory
2 adrenoreceptors is associated with overactive catecholamine release, aggressive remodeling of the left ventricle, worsening signs of heart failure, and shortened life expectancy. Provocatively, deletion polymorphism of the
2 receptor in patients with heart failure also appears to be associated with worse heart failure and poorer outcome.
See p 2491
One may, of course, quibble with some experimental shortcomings. The number of animals is small, and surgical mortality is neither addressed nor accounted for. The magnitude of circulating norepinephrine increase in the at-risk receptor-deficient mice is surprisingly modest. The clinical material has been assessed retrospectively from a database that is poorly described and not available for scrutiny. Furthermore, the experimental model of pressure overload from aortic banding bears little similarity to the syndrome of heart failure observed clinically. Nonetheless, the apparent link between poor outcome and
2 receptor dysfunction certainly provides support for an adverse effect of unfettered sympathetic stimulation on the progression of the syndrome. Indeed, our early observations of a relationship between plasma norepinephrine and mortality in heart failure,2 buttressed by the survival benefit of ß-blocker therapy3,4 appear to have been mechanistically validated.
Or have they? Nothing is simple when dealing with the
2 receptor. It has traditionally been recognized to have at
Related Article:
2-Adrenoceptor Subtypes Prevents Progression of Heart Failure
Circulation 2002 106: 2491-2496.
This article has been cited by other articles:
![]() |
G. Grassi, A. Vincenti, R. Brambilla, F. Q. Trevano, R. Dell'Oro, A. Ciro, G. Trocino, A. Vincenzi, and G. Mancia Sustained Sympathoinhibitory Effects of Cardiac Resynchronization Therapy in Severe Heart Failure Hypertension, November 1, 2004; 44(5): 727 - 731. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. B. Adamson, A. L. Smith, W. T. Abraham, K. J. Kleckner, R. W. Stadler, A. Shih, M. M. Rhodes, and on behalf of the InSync III Model 8042 and Attain Continuous Autonomic Assessment in Patients With Symptomatic Heart Failure: Prognostic Value of Heart Rate Variability Measured by an Implanted Cardiac Resynchronization Device Circulation, October 19, 2004; 110(16): 2389 - 2394. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Latini, S. Masson, I. Anand, M. Salio, A. Hester, D. Judd, S. Barlera, A. P Maggioni, G. Tognoni, J. N Cohn, et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT Eur. Heart J., February 2, 2004; 25(4): 292 - 299. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2002 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |